Moreover, molecular subtypes based on analysis of gene expression patterns [13] as well as more complex analyses of patterns of oncogenic and tumor suppressor pathway activity [14] have identified further subtypes that provide additional insight into the molecular and clinical heterogeneity of HER2+ tumors beyond the original ERBB2+ classification [1-5]. This evidence concerns the gene ERBB2 and neoplasm.